Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 1/20 | 0.34 |
| ▸ | PDE8B | O95263 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22052542 | 1.00 | NR1H2 (0.39) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL21987288 | 1.00 | NR1H2 (0.39) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL26430593 | 0.91 | ALDH1A1 (0.39) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL1914062 | 0.88 | NR1H2 (0.43) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL584023 | 0.88 | NR1H2 (0.43) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL1914060 | 0.88 | NR1H2 (0.43) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL584186 | 0.88 | NR1H2 (0.43) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL21987310 | 0.86 | FKBP1A (0.32) | — | |
| SCHEMBL17042419 | 0.85 | GPR119 (0.39) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL22052541 | 0.84 | ALDH1A1 (0.37) | NR1H2ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-02 | — | — | US | disclosed |
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172532-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HCCS, PYGL | NR1H2 24/4885ALDH1A1 1615/4885MEN1 4390/4885 |
| US-11639350-B2 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | HCCS, HAVCR2, NR1H4 | NR1H2 37/4885ALDH1A1 1584/4885MEN1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.